Photo: File.

The New Molecules Committee (CMN) of the Federal Commission for the Protection against Sanitary Risks (Cofepris), of Mexico,

granted a favorable technical opinion to the Sovereign 02 vaccine.

On this occasion, the evidence was presented for the use of the Sovereign 02 vaccine as primary vaccination in adults, that is, for the population that has not been previously immunized.

This product consists of a recombinant SARS-CoV-2 protein S receptor binding domain (RBD) protein conjugate with tetanus toxoid, with aluminum hydroxide as adjuvant.

It should be noted that the vaccine, presented by Neuronic Mexicana SA de CV and the Finlay Vaccine Institute,

is the second of Latin American origin to be evaluated before this group of experts, followed by Abdala, the first Hispanic-American biological agent against COVID-19, presented on March 31. August 2021.

Cofepris specifies that the CMN is an auxiliary consultation body that is part of the regulatory agency;

issues non-binding opinions on medicines and health supplies, based on the scientific and medical evidence presented.

The result represents a step prior to emergency use authorization, Biocubafarma said on its Twitter account.

The Cuban vaccine #Soberana02 receives a favorable technical opinion from the New Molecules Committee, according to the Mexican regulatory entity @COFEPRIS.


The result represents a step prior to authorizing emergency use.

#VacunasCubanas#CubaPorLaVida pic.twitter.com/yu3PqdPNc8

– Finlay Vaccine Institute (@FinlayInstituto) September 10, 2022

(With information from the Government of Mexico)